- Home
- NEO vs NVCR Comparison
NEO vs NVCR Comparison
Compare NEO & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEO | NVCR |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1999 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NEO | NVCR |
|---|---|---|
| Price | $11.42 | $10.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $11.38 | ★ $26.42 |
| AVG Volume (30 Days) | ★ 1.9M | 1.4M |
| Earning Date | 02-17-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $709,162,000.00 | $642,269,000.00 |
| Revenue This Year | $10.86 | $10.64 |
| Revenue Next Year | $9.70 | $5.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 10.10 | ★ 11.17 |
| 52 Week Low | $4.72 | $9.82 |
| 52 Week High | $14.73 | $24.73 |
Technical Indicators
Market Signals| Indicator | NEO | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 37.64 | 27.03 |
| Support Level | $11.24 | $9.82 |
| Resistance Level | $12.68 | $12.91 |
| Average True Range (ATR) | 0.51 | 0.63 |
| MACD | -0.18 | -0.36 |
| Stochastic Oscillator | 5.85 | 10.51 |
Price Performance
Historical ComparisonAbout NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.